CaaS Capital Management
VC Fund
New York, United States
CaaS Capital Management is a single family office that is investing across all regions, industries, and capital structures. CaaS feels strongly in providing liquidity to partners and stakeholders and pursues this objective with great vigor and energy. CaaS uses a unique combination of fundamental and quantitative inputs when making investmentdecisions.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries CaaS Capital Management invests in
Stages CaaS Capital Management invests in
Countries CaaS Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Frank Fu
|
|||
Mikhail Shilshtut
|
|||
Investment Focus
Industry
- Biotechnology 10 (100%)
- Biopharma 5 (50%)
- Health Care 4 (40%)
- Therapeutics 4 (40%)
- Genetics 2 (20%)
Stage
- Series B 4 (40%)
- Post-IPO Equity 3 (30%)
- Series C 2 (20%)
- Private Equity 1 (10%)
Country
- United States 9 (90%)
- Germany 1 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Frank Fu
Chief Investment Officer
|
Chief Investment Officer | Total investments: 0 | Find email | |
|
Mikhail Shilshtut
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Solid Biosciences
|
Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has anestimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial. | $75M / Post-IPO Equity / Sep 30, 2022 | |
Ventyx Biosciences
|
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. | $176.6M / Post-IPO Equity / Sep 19, 2022 | |
2seventy bio
|
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021. | $170M / Post-IPO Equity / Mar 16, 2022 | |
HotSpot Therapeutics
|
HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M / Series C / Nov 29, 2021 | |
T-knife
|
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen. | $110M / Series B / Aug 02, 2021 | |
Umoja Biopharma
|
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $210M / Series B / Jun 15, 2021 | |
Rapid Micro Biosystems
|
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $81M / Private Equity / Mar 16, 2021 | |
StrideBio
|
StrideBio is a gene therapy company focused on developing genetic medicines with curative potential for patients with devastating conditions. It leverages its proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes toovercome current limitations of first-generation gene therapies. The company was founded in 2015 and is headquartered in Durham, North Carolina. | $81.5M / Series B / Mar 16, 2021 | |
Cyteir Therapeutics
|
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $80M / Series C / Feb 11, 2021 | |
Werewolf Therapeutics
|
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $72M / Series B / Jan 07, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does CaaS Capital Management invest in?
CaaS Capital Management invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series B and Post-IPO Equity stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CaaS Capital Management?
Public channels for CaaS Capital Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CaaS Capital Management?
The team at CaaS Capital Management includes Frank Fu (Chief Investment Officer) and Mikhail Shilshtut (Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
